- Target disease: Mycetoma
- Main partners (since project start): Eisai Co., Ltd., Japan; Erasmus Medical Center, The Netherlands; Free University Amsterdam, The Netherlands; Institute of Endemic Diseases (IEND), Khartoum University, Sudan; Mycetoma Research Centre (MRC), Soba University Hospital, Khartoum, Sudan; Radboud University Medical Center, The Netherlands.
- Project start: September 2015
- Funding (since project start): Bill & Melinda Gates Foundation, USA; Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs, (DGIS); Global Health Innovative Technology (GHIT) Fund, Japan.
Treating eumycetoma is a challenge. Currently, the antifungals ketoconazole and itraconazole are the only therapies available but these are expensive, ineffective, and have serious side effects. Patients often have to undergo amputation, and often more than once, sometimes resulting in death. Safe, effective antifungal agents that are appropriate for use in rural settings are urgently needed. Fosravuconazole (E1224), an orally bioavailable azole that is under development for Chagas disease, may be an effective and affordable treatment for eumycetoma. Fosravuconazole, a prodrug, is rapidly converted to ravuconazole, which has been shown to have potent in vitro activity against one of the causative agents of eumycetoma, Madurella mycetomatis. Its pharmacokinetic properties are favourable and its toxicity is low.
After receiving regulatory and ethical approval in March 2017, the Mycetoma Research Centre, a WHO Collaborating Centre, began recruiting patients into the first-ever double-blind, randomized Phase II/III clinical trial for eumycetoma. The clinical trial, which plans to recruit 138 patients, evaluates the efficacy of the anti-fungal fosravuconazole in moderate lesions in comparison with the current treatment, itraconazole.
The primary objective of this single-centre study conducted in Sudan is to demonstrate the superiority of fosravuconazole over itraconazole after 12 months’ treatment. By the end of 2017, 20 patients had been enrolled into the trial, a pace of enrolment that was slower than anticipated. In 2018, a satellite site will be established to screen more patients and refer them for treatment and care
Protocols of the phase II/III aiming at assessing the comparative efficacy, safety, and tolerability of fosravuconazole in patients with eumycetoma caused by Madurella mycetomatis.were finalized in 2016 and recruitment of patients (with a target of 136 participants) should start early 2017. An interim analysis will be conducted at three months.
Last update: August 2018